MacroGenics (NASDAQ: MGNX) Q4 2024 Earnings Call Mar 20, 2025, 4:30 p.m. ET ...

I'm pleased to share that enrollment is complete in the ongoing LORIKEET phase 2 trial, a 150-patient randomized study for lorigerlimab in combination with docetaxel versus docetaxel alone in ...

"We concluded 2024 with the achievement of multiple clinical development milestones, including the completion of enrollment in the LORIKEET Phase 2 study evaluating lorigerlimab in combination with ...

Enrollment is now complete in the ongoing LORIKEET Phase 2 trial, a 150 patient randomized study of lorigerlimab in combination with docetaxel vs. docetaxel alone in second-line, chemotherapy ...

Good afternoon. We will begin the MacroGenics fourth quarter and full year 2024 corporate progress and financial results conference call in just a moment. All participants are in a listen-only ...

MacroGenics Inc. (MGNX) announced its fourth-quarter 2024 earnings, reporting a narrower-than-expected loss per share and a significant revenue increase. The company’s stock experienced a slight ...